JP7088918B2 - 眼薬徐放性製剤およびその利用 - Google Patents

眼薬徐放性製剤およびその利用 Download PDF

Info

Publication number
JP7088918B2
JP7088918B2 JP2019516703A JP2019516703A JP7088918B2 JP 7088918 B2 JP7088918 B2 JP 7088918B2 JP 2019516703 A JP2019516703 A JP 2019516703A JP 2019516703 A JP2019516703 A JP 2019516703A JP 7088918 B2 JP7088918 B2 JP 7088918B2
Authority
JP
Japan
Prior art keywords
drug
polymer
eye
formulation
solid matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019516703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534872A (ja
Inventor
ウッケーデ，ディーパンク
ジョーンズ，キャサリン
ワイズマン，デイビッド
Original Assignee
マティ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マティ セラピューティクス，インク． filed Critical マティ セラピューティクス，インク．
Publication of JP2019534872A publication Critical patent/JP2019534872A/ja
Priority to JP2022093373A priority Critical patent/JP7324342B2/ja
Application granted granted Critical
Publication of JP7088918B2 publication Critical patent/JP7088918B2/ja
Priority to JP2023122928A priority patent/JP2023133438A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00772—Apparatus for restoration of tear ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
JP2019516703A 2016-09-30 2017-09-30 眼薬徐放性製剤およびその利用 Active JP7088918B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022093373A JP7324342B2 (ja) 2016-09-30 2022-06-09 眼薬徐放性製剤およびその利用
JP2023122928A JP2023133438A (ja) 2016-09-30 2023-07-28 眼薬徐放性製剤およびその利用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402938P 2016-09-30 2016-09-30
US62/402,938 2016-09-30
PCT/US2017/054654 WO2018064648A1 (fr) 2016-09-30 2017-09-30 Formulation ophtalmique à libération pharmacologique prolongée et ses utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022093373A Division JP7324342B2 (ja) 2016-09-30 2022-06-09 眼薬徐放性製剤およびその利用

Publications (2)

Publication Number Publication Date
JP2019534872A JP2019534872A (ja) 2019-12-05
JP7088918B2 true JP7088918B2 (ja) 2022-06-21

Family

ID=61763607

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019516703A Active JP7088918B2 (ja) 2016-09-30 2017-09-30 眼薬徐放性製剤およびその利用
JP2022093373A Active JP7324342B2 (ja) 2016-09-30 2022-06-09 眼薬徐放性製剤およびその利用
JP2023122928A Pending JP2023133438A (ja) 2016-09-30 2023-07-28 眼薬徐放性製剤およびその利用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022093373A Active JP7324342B2 (ja) 2016-09-30 2022-06-09 眼薬徐放性製剤およびその利用
JP2023122928A Pending JP2023133438A (ja) 2016-09-30 2023-07-28 眼薬徐放性製剤およびその利用

Country Status (10)

Country Link
US (2) US11324693B2 (fr)
EP (2) EP3518897B1 (fr)
JP (3) JP7088918B2 (fr)
KR (1) KR20190061047A (fr)
CN (1) CN110475543B (fr)
CA (1) CA3038115A1 (fr)
DK (1) DK3518897T3 (fr)
ES (1) ES2907847T3 (fr)
IL (1) IL265677A (fr)
WO (1) WO2018064648A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3518897T3 (da) * 2016-09-30 2022-03-07 Mati Therapeutics Inc Depotformulering af optalmisk lægemiddel og anvendelser deraf
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500328A (ja) 2002-07-15 2006-01-05 アルコン，インコーポレイテッド 眼内使用のための非ポリマー親油性薬学的インプラント組成物
US20090196905A1 (en) 2008-02-06 2009-08-06 Spada Lon T Stabilization of mitochondrial membranes in ocular diseases and conditions
JP2010513555A (ja) 2006-12-19 2010-04-30 アラーガン、インコーポレイテッド 眼内使用のための環状脂質インプラントの製造法
JP2012515628A (ja) 2009-01-23 2012-07-12 キュー エル ティー インク． １つまたは複数の薬剤の徐放性送達
JP2013518049A (ja) 2010-01-22 2013-05-20 アラーガン、インコーポレイテッド 治療薬持続放出型腔内インプラント
WO2016037169A1 (fr) 2014-09-06 2016-03-10 Integral Biosystems Llc Méthodes et compositions biocompatibles pour obtenir une libération prolongée de médicament dans l'œil

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179583A1 (fr) * 1984-10-04 1986-04-30 Merck & Co. Inc. Système pour augmenter la vitesse de dissolution dans l'eau et la solubilité de médicaments peu solubles
US5273530A (en) 1990-11-14 1993-12-28 The University Of Rochester Intraretinal delivery and withdrawal instruments
JP4194114B2 (ja) * 1994-02-23 2008-12-10 ビーエム リサーチ エイ／エス 制御放出組成物
US5632773A (en) * 1994-05-03 1997-05-27 Allergan, Inc. Biostable corneal implants
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
WO2001049352A2 (fr) 2000-01-03 2001-07-12 Johns Hopkins University Dispositif et procede destines a une pose manuelle de catheter dans une veine retinienne
US6954933B2 (en) 2000-10-30 2005-10-11 Microsoft Corporation Method and apparatus for providing and integrating high-performance message queues in a user interface environment
AU2004215898A1 (en) 2003-02-26 2004-09-10 Medivas, Llc Bioactive stents and methods for use thereof
US7662864B2 (en) 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20050129731A1 (en) 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20080231987A1 (en) 2004-01-19 2008-09-25 Koninklijke Philips Electronic, N.V. Disk Cartridge Having Centering Means
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8529927B2 (en) 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
EP1765454B1 (fr) 2004-07-02 2016-04-13 Mati Therapeutics Inc. DISPOSITIF DE MISE EN PLACE D'UN MOYEN DE TRAITEMENT POUR l'OEIL
AU2005271700B2 (en) 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
EP1787643A1 (fr) * 2004-09-09 2007-05-23 Jimenez Bayardo, Arturo Implants et microspheres de liberation prolongee de medicaments a usage ophtalmique et methodes de preparation
WO2006031658A2 (fr) * 2004-09-10 2006-03-23 Allergan, Inc. Inserts therapeutiques pour canal lacrymal et methodes connexes
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
CN101069004A (zh) 2005-04-04 2007-11-07 京商株式会社 多缸两冲程星形内燃机
US7998497B2 (en) 2006-03-31 2011-08-16 Qlt Inc. Nasolacrimal drainage system implants for drug therapy
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
AU2007325409B2 (en) * 2006-11-09 2013-03-28 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
JP4309438B2 (ja) 2007-03-20 2009-08-05 株式会社東芝 情報記録再生装置
US7839044B2 (en) 2007-03-23 2010-11-23 Panasonic Corporation Rotor magnet, spindle motor comprising the same, recording and reproducing apparatus, and jig for manufacturing the same
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
CA2716110A1 (fr) * 2008-02-21 2009-08-27 Tim Mcnamara Ains ophtalmiques utilises comme adjuvants
CA2781629A1 (fr) 2009-11-27 2011-06-03 Sascha K. Zarins Implants lacrimaux contenant un noyau de medicament fendu et inserable
EP4122384A1 (fr) 2011-06-16 2023-01-25 Abbott Diabetes Care, Inc. Dispositifs de surveillance d'analytes à compensation thermique, systèmes et procédés associés
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
RU2629449C2 (ru) 2014-05-07 2017-08-29 Общество С Ограниченной Ответственностью "Яндекс" Устройство, а также способ выбора и размещения целевых сообщений на странице результатов поиска
US10603274B2 (en) * 2016-09-30 2020-03-31 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
DK3518897T3 (da) * 2016-09-30 2022-03-07 Mati Therapeutics Inc Depotformulering af optalmisk lægemiddel og anvendelser deraf
US10880072B2 (en) 2018-06-20 2020-12-29 Verizon Patent And Licensing Inc. Systems and methods for controlled random endorsement in a blockchain network
US11695537B2 (en) 2021-06-01 2023-07-04 Bose Corporation Digital signal processor/network synchronization

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500328A (ja) 2002-07-15 2006-01-05 アルコン，インコーポレイテッド 眼内使用のための非ポリマー親油性薬学的インプラント組成物
JP2010513555A (ja) 2006-12-19 2010-04-30 アラーガン、インコーポレイテッド 眼内使用のための環状脂質インプラントの製造法
US20090196905A1 (en) 2008-02-06 2009-08-06 Spada Lon T Stabilization of mitochondrial membranes in ocular diseases and conditions
JP2012515628A (ja) 2009-01-23 2012-07-12 キュー エル ティー インク． １つまたは複数の薬剤の徐放性送達
JP2013518049A (ja) 2010-01-22 2013-05-20 アラーガン、インコーポレイテッド 治療薬持続放出型腔内インプラント
WO2016037169A1 (fr) 2014-09-06 2016-03-10 Integral Biosystems Llc Méthodes et compositions biocompatibles pour obtenir une libération prolongée de médicament dans l'œil

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
「Poloxamer 407, NF」，Spectrum Product Details [online]，Spectrum Chemical Mfg. Corp.，https://www.spectrumchemical.com/OA_HTML/chemical-products_Poloxamer-407-NF_P1166.jsp?minisite=10020&respid=22372&phrase=Pluronic%20F127，[検索日:2021/4/15]
編：日本医薬品添加剤協会，医薬品添加物事典 2007，株式会社薬事日報社，2007年，p.179「チロキサポール」の項

Also Published As

Publication number Publication date
CN110475543B (zh) 2023-07-25
EP3518897A1 (fr) 2019-08-07
DK3518897T3 (da) 2022-03-07
US11957784B2 (en) 2024-04-16
CN110475543A (zh) 2019-11-19
ES2907847T3 (es) 2022-04-26
EP4046609A1 (fr) 2022-08-24
KR20190061047A (ko) 2019-06-04
US20200222317A1 (en) 2020-07-16
US20230091568A1 (en) 2023-03-23
JP2023133438A (ja) 2023-09-22
CA3038115A1 (fr) 2018-04-05
US11324693B2 (en) 2022-05-10
JP2022125050A (ja) 2022-08-26
WO2018064648A1 (fr) 2018-04-05
JP2019534872A (ja) 2019-12-05
IL265677A (en) 2019-05-30
JP7324342B2 (ja) 2023-08-09
EP3518897B1 (fr) 2022-02-09
EP3518897A4 (fr) 2020-05-27

Similar Documents

Publication Publication Date Title
US20200323685A1 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP7324342B2 (ja) 眼薬徐放性製剤およびその利用
US20140025022A1 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US10603274B2 (en) Ophthalmic drug sustained release formulation and uses thereof
JP2023071958A (ja) 涙腺移植片用静的ピン挿入ツール
JP6213560B2 (ja) 薬剤送達システムならびに開放隅角緑内障および高眼圧症を治療する方法
CA3095460A1 (fr) Formulation de medicament ophtalmique a liberation prolongee et utilisations pour le traitement du syndrome de l'oeil sec

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200716

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220609

R150 Certificate of patent or registration of utility model

Ref document number: 7088918

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150